Natural killer cell alloreactivity for leukemia therapy.
Donor-versus-recipient natural killer (NK) cell alloreactivity derives from a mismatch between donor NK clones, carrying specific inhibitory receptors for self MHC class I molecules, and MHC class I ligands on recipient cells. When faced with mismatched allogeneic targets, these donor NK clones sense the missing expression of self HLA class I alleles and mediate alloreactions. Transplantation from NK alloreactive haploidentical donors controls acute myeloid leukemia relapse and improves engraftment without causing graft-versus-host disease.
Ruggeri
Loredana
L
Division of Hematology and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Perugia, 06122 Perugia, Italy.
Mancusi
Antonella
A
Perruccio
Katia
K
Burchielli
Emanuela
E
Martelli
Massimo F
MF
Velardi
Andrea
A
D000818:Animals; D015234:HLA-A Antigens / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive; D007694:Killer Cells, Natural / Q000276:immunology*; D007938:Leukemia / Q000628:therapy*; D051379:Mice; D014184:Transplantation, Homologous
D015234:HLA-A Antigens